ZBTB16

Across TCGA pan-cancer cohorts, ZBTB16 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZBTB16 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZBTB16 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB16 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, BRCA, and ESCA are the cancer types where ZBTB16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.977	0.825	.005	20	view →
BRCA	OS	Median	III,IV	0.165	0.833	<.001	12	view →
ESCA	OS	Median	All	0.080	0.681	<.001	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.708	.033	2	view →
SKCM	DFS	Median	All	0.096	0.210	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZBTB16–UCEC (DFS)

Open the UCEC breakdown →